Medical Device Procurement: Why I Use Completely Different Processes for Electric Wheelchairs and Hematology Analyzers

There's no universal playbook for medical device procurement. I learned that the hard way.

When I took over purchasing for our clinic network in 2020—five clinical departments, around 200 beds—I figured I had it sorted. Get quotes, compare line items, pick the middle option, move on. It worked for office supplies, so I assumed it'd work here too.

Then, in the same quarter, I was asked to buy a Permobil electric wheelchair for our rehabilitation department and a hematology analyzer for our lab. I ran both through the exact same process. And I got burned both times—in different ways.

What I eventually built instead was a scenario-based approach. Not one method, but three. Which one applies to you depends on what you're actually buying. Here's the breakdown I wish I'd had two years ago.

Scenario A: Mobility Equipment (Electric Wheelchairs and Patient Lifts)

This covers anything that comes into direct contact with patients and gets used by nursing staff every day. Permobil's electric wheelchair line, patient lifts, seating systems, battery packs—all of it falls into this category.

Why the procurement logic is different here

Because nearly half the cost isn't on the purchase order. It's in the battery replacement, the sling that tears after six months, and the day a nurse can't transfer a patient because the equipment failed without warning.

In 2022, we bought three patient lifts from a discount supplier to save money. They were about 35% cheaper per unit. By month nine, two of the three were throwing motor fault errors. Repair costs, plus downtime, plus temporary rental fees—we ended up spending more overall than if we'd bought higher-end models upfront. Our rehab director made a point of telling me—"don't do that again." (Noted.)

What "value over price" actually means here

Do the math and it becomes obvious. If a device has a seven-year design life and replacement costs a third of the purchase price, a device that lasts the full seven years ends up cheaper than the one that dies in year three.

According to FDA device classification (accessed from fda.gov, December 2024), electric wheelchairs are Class II devices—meaning they require premarket notification (510(k) clearance) to be legally marketed in the U.S. For procurement purposes, that means asking for the 510(k) number before approving any order. If a quote seems too good to be true, that one-minute verification is worth the time.

On Permobil products specifically: the technical documentation we received (error code definitions, battery replacement schedules, maintenance intervals) actually cut our downtime. When a chair threw a battery fault code, our in-house technician could pull up the manual and determine whether it needed a field replacement or a full service call. That's a real cost saving—just not one that shows up in the quote.

A rookie mistake that cost me

I assumed "standard configuration" meant the same thing across every vendor. It doesn't. We ordered chairs with a standard 18-inch seat width. Turns out most of our high-demand patients in one department needed either 20-inch or custom seating. We ended up paying roughly $800 extra per chair for the upgrade—or working with equipment that didn't quite fit.

Now, before I approve any mobility equipment, I verify three things: patient weight range, caregiver working height requirements during use, and battery replacement frequency (three months? six months? annually?—it changes the budget picture considerably).

Scenario B: Diagnostic and Laboratory Equipment (Hematology Analyzers and Biosensors)

This is almost the opposite game. The purchase price is usually about a third of the total cost. The other two-thirds are hidden in reagents, in quality control materials, and in the reality that you signed a five-year contract for a device that may be technologically outdated in two.

Hematology analyzers are the classic example. You see a price on a dealer quote—say, $20,000 (illustrative)—and it seems reasonable. But you don't know the true cost per test until you've read the reagent pricing clause.

My first lesson: we leased an analyzer with a monthly fee that looked low. It was low because the device was designed to be locked into reagent sales. The contract pegged specific reagents at a fixed price for four years, while market rates had already dropped. We overpaid by roughly $11,000 over the contract period. That money never appeared on a purchase order—it was buried in monthly invoices.

So for diagnostic equipment, the key metric isn't the device price. It's cost per test—and volume flexibility clauses in the contract.

While we're here—what is a biosensor, exactly?

If you're buying diagnostic equipment, "biosensor" comes up a lot, often with a markup attached. Simply put: a biosensor is a detection device that combines a biological recognition element (like an enzyme, antibody, or DNA probe) with a transducer that converts a biological response into a measurable electrical signal.

In a hematology analyzer, that means sensors detect specific substances in a blood sample—glucose, electrolytes, proteins—and turn them into readings. Some analyzers use many biosensors, others use different detection technologies. If a supplier emphasizes "biosensor" in a bid document or sales pitch, these are the questions worth asking:

• Which specific sensor technology is used for each assay?
• How often do sensors need replacement, and what's the cost?
• Are these sensors suited to your sample volume, or were they designed for higher-throughput labs?

In our Q3 2024 vendor evaluation, sensor replacement costs alone varied by roughly 25% between the two finalists on our shortlist. That's enough of a gap to change the decision.

An honest note on obsolescence

Patient mobility equipment stays technologically relevant for seven to ten years. You buy a good electric wheelchair and it's still a functional device five years later. Diagnostic equipment doesn't work that way.

Software updates, panel additions, connectivity standards—these tend to shift in significant cycles every three to five years. Which means that procurement plan you built in early 2024 may already be outdated by early 2025. Before locking in a contract, confirm the manufacturer's update roadmap for the next 18–24 months. If they can't say, that's your signal.

Scenario C: Multi-Department Bundling

This is Scenario A and Scenario B mixed together, and it has its own logic. You're asked to consolidate orders across multiple departments—mobility equipment, diagnostic equipment, possibly physical therapy, surgery, and ICU. The goal is usually to save money or reduce vendor count. But how you bundle matters.

In a 2023 consolidation project, we tried to reduce eight vendors to four. We ended up merging some things we shouldn't have. Mobility equipment and lab equipment don't just require different pricing models—they need completely different service expectations. Mobility equipment failures often need same-day replacement; lab equipment can usually wait for a scheduled maintenance window. Bundle them into one procurement contract, and those service expectations collide.

My rule now: only bundle vendors when the categories share similar maintenance cadence, delivery urgency, and replacement cycles. Otherwise, keep them separate. Procurement will complain about vendor sprawl—but that's better than a department waiting two days for equipment because your consolidated vendor only does quarterly service visits.

How to Figure Out Which Scenario You're In

Honestly, you probably fall into two or three of these at once. But asking three questions in order will get you most of the way there.

Question 1: Does the device touch patients directly and get operated by caregivers daily?

If yes, you're in Scenario A. Prioritize total cost of ownership, service contracts, maintenance documentation, and battery life over the purchase price.

Question 2: Does the device require reagents, calibration, or frequent software updates?

If yes, you're in Scenario B. Shift focus from device price to cost per test and contract terms—especially obsolescence clauses.

Question 3: Are you consolidating multiple departments, or buying for just one?

If multiple, you're in Scenario C. Bundle by shared service cadence, split by divergent service expectations.

If you hit all three, prioritize Scenario B thinking—hidden costs accumulate fastest on diagnostic equipment. If you hit only Scenario A, focus on service and support. If you hit only Scenario C, split the categories before you talk consolidation.

The worst situation I've seen was a clinic that used Scenario B logic to buy Scenario A equipment. They signed a cheap purchase contract, separate servicing, and ended up spending double the purchase price on maintenance in the first year because every service visit carried an extra fee. The reverse is also true—using Scenario A logic on Scenario B (like asking for a "five-year maintenance package" on lab equipment) gets you locked into an expensive deal for a device that may be obsolete before the contract ends.

Medical device procurement isn't a one-size-fits-all job. It's more like triage—you look at the characteristics of what you're buying, then decide which method applies. That's the lesson that took me two years and a few uncomfortable conversations to learn. Hopefully it saves you the tuition.

This reflects my experience as of January 2025. Prices, regulations, and technology change quickly—verify current data before any purchase decision.